对乙酰氨基酚与布洛芬治疗儿童中枢神经系统疟疾:一项随机临床试验
在赞比亚和马拉维的三家医院开展随机临床试验,纳入256名2至11岁中枢神经系统疟疾患儿,比较规定时间联用对乙酰氨基酚与布洛芬的积极退热方案与仅体温≥38.5°C时按需给对乙酰氨基酚的常规方案。积极退热组72小时内最高体温更低(38.6 vs 39.2°C),多次或持续癫痫发作的比值比更低(OR 0.26),寄生虫清除时间无组间差异。
要点
- 积极退热组72小时最高体温38.6°C,低于常规组的39.2°C(差值-0.62°C)。
- 积极退热组多次或持续癫痫发作10例(8%),常规组34例(27%)(OR 0.26)。
- 两组寄生虫清除时间未检出差异,严重不良事件分别为15例(12%)和25例(20%)。
核心结论
- 本研究发现积极退热治疗将平均最高体温降至与既往观察性研究中无神经功能损害儿童相当的水平,并改善了急性癫痫发作结局,且未延长寄生虫血症。
研究设计与样本
- 随机临床试验,在赞比亚1家三级医院和1家地区医院以及马拉维1家三级中心的住院儿科开展。
- 纳入2至11岁中枢神经系统疟疾患儿(排除肌酐>1.2 mg/dL者),2019年至2022年入组,共256名参与者(每组128名)。
- 数据分析于2022年12月至2023年4月进行。
主要发现
- 积极退热组最高体温38.6°C,常规组39.2°C(差值-0.62°C;95%CI,-0.82至-0.42;P<.001)。
- 积极退热组多次或持续癫痫发作10例(8%),常规组34例(27%)(OR,0.26;95%CI,0.12至0.56)。
- 未检出两组寄生虫清除时间的差异。
- 严重不良事件40例(15%):常规组25例(20%),积极退热组15例(12%),包括13例死亡(分别为10例[8%]和3例[2%])。
- 因肌酐升高停药:常规组8例(6%),积极退热组13例(10%)(OR,1.74;95%CI,0.63至5.07)。
关键数值与推荐
- 积极退热方案:对乙酰氨基酚(负荷量30 mg/kg,之后15 mg/kg)加布洛芬10 mg/kg,每6小时一次,不论临床体温,持续72小时。
- 常规方案:对乙酰氨基酚15 mg/kg,按需每6小时一次,用于体温38.5°C或以上。
- 主要结局为72小时(总随访时间)内的最高体温。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A third of children who survive malaria with neurological involvement (central nervous system [CNS] malaria) develop sequelae. A higher maximum temperature (Tmax) and seizures are risk factors for sequelae. OBJECTIVE: To compare aggressive antipyretic therapy using scheduled acetaminophen and ibuprofen vs usual care with acetaminophen alone given only for a temperature of 38.5 °C or higher. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted at inpatient pediatric services of 1 tertiary care and 1 district hospital in Zambia and a tertiary care center in Malawi. Included were children aged 2 to 11 years with CNS malaria (excluding those with creatinine >1.2 mg/dL), who were enrolled from 2019 to 2022. Data analysis took place from December 2022 to April 2023. INTERVENTION: The aggressive antipyretic group received acetaminophen (30 mg/kg load, then 15 mg/kg) plus ibuprofen, 10 mg/kg, every 6 hours, regardless of clinical temperature for 72 hours. The usual care group received 15 mg/kg of acetaminophen as needed every 6 hours for a temperature of 38.5 °C or higher. MAIN OUTCOMES AND MEASURES: The primary outcome variable was Tmax over 72 hours, the total duration of follow-up. Secondary outcomes included seizures and parasite clearance. RESULTS: Five hundred fifty-three patients were screened, 226 (40.9%) were ineligible, and 57 (10.3%) declined. A total 256 participants (n = 128/group) had a mean (SD) age of 4.3 (2.1) years; 115 (45%) were female, and 141 (55%) were male. The aggressive antipyretic group had a lower Tmax, 38.6 vs 39.2 °C (difference, -0.62 °C; 95% CI, -0.82 to -0.42; P < .001) and lower odds of experiencing multiple or prolonged seizures, 10 (8%) vs 34 children (27%) in the usual care group (odds ratio [OR], 0.26; 95% CI, 0.12 to 0.56). No group difference in parasite clearance time was detected. Severe adverse events occurred in 40 children (15%), 25 (20%) in the usual care group and 15 (12%) in the aggressive antipyretic group, including 13 deaths (10 [8%] and 3 [2%], respectively). Increased creatinine resulted in study drug discontinuation in 8 children (6%) in the usual care group and 13 children (10%) in the aggressive antipyretic group (OR, 1.74; 95% CI, 0.63 to 5.07). CONCLUSIONS AND RELEVANCE: This study found that aggressive antipyretic therapy reduced mean Tmax to temperature levels comparable with the Tmax among children without neurological impairments in prior observational studies and improved acute seizure outcomes with no prolongation of parasitemia. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03399318.
引用
- Birbeck GL, Seydel KB, Mwanza S, et al. Acetaminophen and Ibuprofen in Pediatric Central Nervous System Malaria: A Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 38857015. doi:10.1001/jamaneurol.2024.1677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。